It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PRTC’s FA Score shows that 0 FA rating(s) are green whileXOMAO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PRTC’s TA Score shows that 5 TA indicator(s) are bullish while XOMAO’s TA Score has 3 bullish TA indicator(s).
PRTC (@Biotechnology) experienced а -9.63% price change this week, while XOMAO (@Biotechnology) price change was -1.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.
PRTC is expected to report earnings on Aug 27, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
PRTC | XOMAO | PRTC / XOMAO | |
Capitalization | 432M | N/A | - |
EBITDA | N/A | N/A | - |
Gain YTD | -6.555 | 5.160 | -127% |
P/E Ratio | 8.17 | N/A | - |
Revenue | N/A | N/A | - |
Total Cash | N/A | 93.3M | - |
Total Debt | N/A | 114M | - |
PRTC | XOMAO | |
---|---|---|
RSI ODDS (%) | 4 days ago80% | 4 days ago24% |
Stochastic ODDS (%) | 4 days ago82% | 4 days ago29% |
Momentum ODDS (%) | 4 days ago80% | 4 days ago22% |
MACD ODDS (%) | 4 days ago79% | 4 days ago14% |
TrendWeek ODDS (%) | 4 days ago76% | 4 days ago23% |
TrendMonth ODDS (%) | 4 days ago77% | 4 days ago21% |
Advances ODDS (%) | 15 days ago80% | 28 days ago22% |
Declines ODDS (%) | 4 days ago82% | 15 days ago23% |
BollingerBands ODDS (%) | 4 days ago89% | 4 days ago38% |
Aroon ODDS (%) | 4 days ago70% | 4 days ago19% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FBTCX | 22.09 | 0.21 | +0.96% |
Fidelity Advisor Biotechnology C | |||
JNVSX | 19.01 | 0.05 | +0.26% |
Jensen Quality Mid Cap J | |||
FIJZX | 52.51 | 0.09 | +0.17% |
Fidelity Advisor Consumer Discret Z | |||
LTAGX | 16.31 | 0.01 | +0.06% |
Lord Abbett International Growth R5 | |||
FRIFX | 12.17 | -0.03 | -0.25% |
Fidelity Real Estate Income |
A.I.dvisor indicates that over the last year, PRTC has been loosely correlated with IRON. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTC jumps, then IRON could also see price increases.
Ticker / NAME | Correlation To PRTC | 1D Price Change % | ||
---|---|---|---|---|
PRTC | 100% | -3.90% | ||
IRON - PRTC | 34% Loosely correlated | +1.68% | ||
ZLAB - PRTC | 31% Poorly correlated | +2.58% | ||
AUTL - PRTC | 28% Poorly correlated | -0.85% | ||
MDWD - PRTC | 28% Poorly correlated | -0.80% | ||
OABI - PRTC | 27% Poorly correlated | +4.79% | ||
More |
A.I.dvisor tells us that XOMAO and XOMAP have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XOMAO and XOMAP's prices will move in lockstep.
Ticker / NAME | Correlation To XOMAO | 1D Price Change % | ||
---|---|---|---|---|
XOMAO | 100% | -0.56% | ||
XOMAP - XOMAO | 23% Poorly correlated | +0.59% | ||
PBM - XOMAO | 22% Poorly correlated | -4.07% | ||
DARE - XOMAO | 21% Poorly correlated | -5.88% | ||
PRTC - XOMAO | 21% Poorly correlated | -3.90% | ||
IBIO - XOMAO | 20% Poorly correlated | -0.13% | ||
More |